Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | -4.55% | +0.64% | -29.92% |
Financials (USD)
Sales 2024 * | 225M | Sales 2025 * | 321M | Capitalization | 480M |
---|---|---|---|---|---|
Net income 2024 * | -283M | Net income 2025 * | -148M | EV / Sales 2024 * | 2.63 x |
Net Debt 2024 * | 112M | Net Debt 2025 * | 118M | EV / Sales 2025 * | 1.86 x |
P/E ratio 2024 * |
-1.86
x | P/E ratio 2025 * |
-3.73
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.81% |
Latest transcript on Travere Therapeutics, Inc.
1 day | -4.55% | ||
1 week | +0.64% | ||
Current month | +13.92% | ||
1 month | -5.83% | ||
3 months | -25.71% | ||
6 months | +12.90% | ||
Current year | -29.92% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 19-01-03 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 14-07-31 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 22-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 15-03-30 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 14-10-07 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 20-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 6.3 | -4.55% | 974,836 |
24-05-09 | 6.6 | -3.23% | 1,198,179 |
24-05-08 | 6.82 | +1.04% | 1,229,505 |
24-05-07 | 6.75 | +3.05% | 1,938,139 |
24-05-06 | 6.55 | +4.63% | 1,383,054 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.92% | 480M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- TVTX Stock